BCRX BioCryst Pharmaceuticals Inc
$7.78
▼ 3.0%Updated Oct 16, 2:25 PM ET
Report Card
BCRX at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.
Key Metrics
Market Cap
—
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
—
Interest Coverage
3.15x
Current Ratio
2.32x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
Not rated
Business Overview
BioCryst Pharmaceuticals Inc (BCRX) is a NASDAQ-listed company in the Biotechnology industry, within the Health Care sector.
In its latest reported year it generated about $874.84M in revenue and $263.86M in net profit.
Our model hasn't rated BCRX yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedThe numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
2.4% average over the last 3 years
±287.4 pts around -221.4% across 10 years
grew in 6 of the last 9 year-over-year periods
positive in 1 of 10 years
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Revenue Growth
4Y CAGR
53.6%
Revenue moved from $26.35M in 2016 to $874.84M in 2025, a 47.6% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
—
Operating Margin
39.0%
Net Margin
30.2%
ROE
—
Debt Analysis
Total Debt
$298.14M
Net Debt
$143.17M
Net Debt / EBITDA
0.42x
Debt / Equity
—
Leverage: debt-to-equity is n/a, and operating profit covers interest about 3.1x, with a current ratio of 2.3x. Detailed balance-sheet leverage is limited for this name. It carries roughly $298.14M of total debt against $154.97M of cash.
Cash Flow Analysis
Operating CF
$347.37M
Free Cash Flow
$344.90M
FCF Margin
39.4%
In the latest year BioCryst Pharmaceuticals Inc produced about $347.37M of operating cash flow and $344.90M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
BCRX trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$23.17
Current price
$7.78
Starting FCF (latest 10-K)
$344.90M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where BCRX sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How BCRX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
BCRX doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.
P/E vs sector
—
median 26.1x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
—
not rated yet
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$18.11 – $30.18
vs. $7.78 today · implied CAGR 18% – 31%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $944.82M | $1.02B | $1.10B | $1.19B | $1.29B |
| Net income | $283.45M | $306.12M | $330.61M | $357.06M | $385.63M |
| EPS | $1.11 | $1.20 | $1.29 | $1.40 | $1.51 |
| Share price (low) | $13.31 | $14.38 | $15.53 | $16.77 | $18.11 |
| Share price (high) | $22.18 | $23.96 | $25.88 | $27.95 | $30.18 |
| CAGR (low–high) | 71% / 185% | 36% / 75% | 26% / 49% | 21% / 38% | 18% / 31% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Analyst Ratings
What 17 Wall Street analysts covering BCRX recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-6 pts of buy ratings).
Latest SEC Filings
BCRX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
BCRX — frequently asked questions
Is BCRX a good stock to buy?
We don't give buy or sell advice. Review BioCryst Pharmaceuticals Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does BCRX's data come from?
Live price data plus the annual financials in BioCryst Pharmaceuticals Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.
How is the 5-year projection for BCRX calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this BCRX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell BCRX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.